<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>47</patient-age><report-id>PHHY2012NZ064606</report-id><gender>male</gender><reactions><reaction>Moderately impaired renal function, stage 3 CKD (chronic kidney disease).</reaction><reaction>Creatinine level was 137 umol/L</reaction><reaction>EGFR was 48 ml/min/1.73m^2</reaction><reaction>Impaired glucose tolerance</reaction><reaction>Mean platelet volume 9.5 fl</reaction><reaction>Dyslipidaemia</reaction><reaction>Eosinophil count was 0.02x10^9/l, 02%</reaction><reaction>Platelets count was 126 x 10^9</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>CLOZARIL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AMISULPRIDE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LITHIUM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LAMOTRIGINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>THYROXINE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Schizophrenia</indication><indication>Affective disorder</indication><indication>Hypothyroidism</indication></indications><outcomes/><country>New Zealand</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053157_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134144</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHY2012NZ064606</safetyreportid>
		<primarysourcecountry>NZ</primarysourcecountry>
		<occurcountry>NZ</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-07-27</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012NZ064606</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Sally</reportergivename>
			<reporterfamilyname>Davidson</reporterfamilyname>
			<reporterorganization>Tacy Street Clinic</reporterorganization>
			<reporterstreet>36 Tacy St, Kilbirnie</reporterstreet>
			<reportercity>Wellington</reportercity>
			<reportercountry>NZ</reportercountry>
			<qualification code="1">Physician</qualification>
			<observestudytype>3</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>SP</patientinitial>
			<patientinvestigationnumb>ETS2090</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19650204</patientbirthdate>
			<patientweight>75</patientweight>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Affective disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypothyroidism</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Psychotic disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Platelet count decreased</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Moderately impaired renal function, stage 3 CKD (chronic kidney disease).</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Chronic kidney disease</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal failure chronic</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Moderately impaired renal function, stage 3 CKD (chronic kidney disease).</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Impaired renal function</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal impairment</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Creatinine level was 137 umol/L</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Creatinine blood increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Blood creatinine increased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120423</reactionstartdate>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>EGFR was 48 ml/min/1.73m^2</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>GFR decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Glomerular filtration rate decreased</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120423</reactionstartdate>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Impaired glucose tolerance</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Glucose tolerance impaired</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Glucose tolerance impaired</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Mean platelet volume 9.5 fl</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Mean platelet volume increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Mean platelet volume increased</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120326</reactionstartdate>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Dyslipidaemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Dyslipidaemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyslipidaemia</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Eosinophil count was 0.02x10^9/l, 02%</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Eosinophil count decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Eosinophil count decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20080310</reactionstartdate>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Platelets count was 126 x 10^9</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Platelet count decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Platelet count decreased</reactionmeddrapt>
				<termhighlighted>2</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20080310</reactionstartdate>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Blood creatinine</testname>
				<testresult>137</testresult>
				<testunit>umol/l</testunit>
				<lowtestrange>77</lowtestrange>
				<hightestrange>119</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080310</testdate>
				<testname>Eosinophil count</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Eosinophil count</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Glomerular filtration rate</testname>
				<testresult>48/1.73</testresult>
				<testunit>mg/m2</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Lymphocyte count</testname>
				<testresult>17</testresult>
				<testunit>%</testunit>
				<lowtestrange>20</lowtestrange>
				<hightestrange>45</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120326</testdate>
				<testname>Mean platelet volume</testname>
				<lowtestrange>5.5</lowtestrange>
				<hightestrange>9.0</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Mean platelet volume</testname>
				<lowtestrange>5.5</lowtestrange>
				<hightestrange>9.0</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121203</testdate>
				<testname>Neutrophil count</testname>
				<testresult>80</testresult>
				<testunit>%</testunit>
				<lowtestrange>40</lowtestrange>
				<hightestrange>75</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080310</testdate>
				<testname>Platelet count</testname>
				<testresult>142</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080407</testdate>
				<testname>Platelet count</testname>
				<testresult>140</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080603</testdate>
				<testname>Platelet count</testname>
				<testresult>136</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20080630</testdate>
				<testname>Platelet count</testname>
				<testresult>194</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120326</testdate>
				<testname>Platelet count</testname>
				<testresult>126</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120423</testdate>
				<testname>Platelet count</testname>
				<testresult>135</testresult>
				<testunit>10^9/L</testunit>
				<lowtestrange>150</lowtestrange>
				<hightestrange>500</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Schizophrenia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2002-10-22</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>287.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>287.5 mg</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2011-03-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>162.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>162.5 mg</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-03-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood creatinine increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyslipidaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Eosinophil count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glomerular filtration rate decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Glucose tolerance impaired</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mean platelet volume increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Platelet count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal failure chronic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AMISULPRIDE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2011-04-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMISULPRIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AMISULPRIDE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>300 mg, UNK</drugdosagetext>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-04-03</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMISULPRIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LITHIUM</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Affective disorder</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2010-10-01</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LITHIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LITHIUM</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugstructuredosagenumb>750</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>750 mg, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2012</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LITHIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LAMOTRIGINE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Affective disorder</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2009</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LAMOTRIGINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LAMOTRIGINE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>300 mg, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2012</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LAMOTRIGINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>THYROXINE</medicinalproduct>
				<obtaindrugcountry>NZ</obtaindrugcountry>
				<drugauthorizationcountry>NZ</drugauthorizationcountry>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypothyroidism</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012NZ064606 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>PMS case report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 27 Jul 2012 with follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 05 Dec 2012: The report refers to 47-years old male patient (NHI No ETS2090). The patient <Semaphore x="1875899" class="Disease or Finding" value="Electrical Exposure" score="1.00" ID="C45407">current </Semaphore>condition included <Semaphore x="3212155" class="MedDRA LLT" value="Psychotic disorder" score="1.00" ID="10061920">psychotic features, <Semaphore x="2238415" class="Disease or Finding" value="Mood Disorder" score="1.00" ID="C92200">mood disorder</Semaphore></Semaphore>, <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore>, <Semaphore x="2042024" class="Disease or Finding" value="Hypothyroidism" score="1.00" ID="C26800">hypothyroidism </Semaphore>and <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count decreased</Semaphore>. The patient concomitant medication included <Semaphore x="102628" class="Medicine" value="Amisulpride" score="0.49" ID="269041">amisulpride</Semaphore>, <Semaphore x="794352" class="Medicine" value="Lithium" score="0.74" ID="278356">lithium</Semaphore>, <Semaphore x="769390" class="Medicine" value="lamotrigine" score="0.49" ID="242792">lamotrigine</Semaphore>, thyroxin (reported as possibly thyroxin because of illegible <Semaphore x="2606034" class="AnatomicStructure" value="Terminal Bar" score="1.00" ID="C33753">word </Semaphore>on source document). The patient received <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.87" ID="247865">Clozaril </Semaphore>(<Semaphore x="385490" class="Medicine" value="Clozapine" score="0.49" ID="252210">clozapine</Semaphore>) for resistant <Semaphore x="2789712" class="MedDRA LLT" value="Bipolar disorder" score="1.00" ID="10057667"><Semaphore x="2238415" class="Disease or Finding" value="Mood Disorder" score="1.00" ID="C92200"><Semaphore x="1595179" class="Disease or Finding" value="Bipolar Disorder" score="1.00" ID="C34423">bipolar <Semaphore x="2238415" class="Disease or Finding" value="Mood Disorder" score="1.00" ID="C92200">mood <Semaphore x="3212155" class="MedDRA LLT" value="Psychotic disorder" score="1.00" ID="10061920">disorder </Semaphore></Semaphore>
       </Semaphore>
      </Semaphore>
     </Semaphore>
    <Semaphore x="3212155" class="MedDRA LLT" value="Psychotic disorder" score="1.00" ID="10061920">and psychotic </Semaphore>features at unknown dose from 22 Oct 2002. It was reported that, the dose of <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.87" ID="247865">Clozaril </Semaphore>was <Semaphore x="2812482" class="MedDRA LLT" value="Blood magnesium decreased" score="1.00" ID="10005654">reduced from 287.5 mg </Semaphore>(March 2011) to 162.5 mg (March 2012). The patient had <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408"><Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">decreased <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore></Semaphore>count </Semaphore>for more than 10 years intermittently, more persistently in last two years. It was also reported that estimated <Semaphore x="2978897" class="MedDRA LLT" value="Glomerular filtration rate decreased" score="1.00" ID="10018358"><Semaphore x="1986326" class="Disease or Finding" value="Glomerular Filtration Rate Decreased" score="1.00" ID="C78326">glomerular filtration rate had <Semaphore x="2804249" class="MedDRA LLT" value="Blood creatinine decreased" score="1.00" ID="10005482">decreased </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="2804249" class="MedDRA LLT" value="Blood creatinine decreased" score="1.00" ID="10005482">and <Semaphore x="2050560" class="Disease or Finding" value="Increased Creatinine" score="1.00" ID="C78249">creatinine </Semaphore></Semaphore>
    <Semaphore x="2804296" class="MedDRA LLT" value="Blood creatinine increased" score="1.00" ID="10005483">
     <Semaphore x="2050560" class="Disease or Finding" value="Increased Creatinine" score="1.00" ID="C78249">already had increased </Semaphore></Semaphore>(reported as decreased and increased) when decision <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">made </Semaphore>to reintroduce <Semaphore x="794352" class="Medicine" value="Lithium" score="0.74" ID="278356">lithium </Semaphore>in late 2010. The patient had mild long standing <Semaphore x="1869448" class="Disease or Finding" value="Dyslipidemia" score="1.00" ID="C80385">dyslipidemia </Semaphore>and <Semaphore x="2979840" class="MedDRA LLT" value="Glucose tolerance impaired" score="1.00" ID="10018429">impaired <Semaphore x="627832" class="Medicine" value="Glucose" score="0.49" ID="269493">glucose </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">tolerance </Semaphore></Semaphore>
    <Semaphore x="2979881" class="MedDRA LLT" value="Glucose tolerance increased" score="1.00" ID="10018431">
     <Semaphore x="2806733" class="MedDRA LLT" value="Blood glucose increased" score="1.00" ID="10005557">increased </Semaphore></Semaphore>in last year. On 10 Mar 2008, the patient laboratory data showed <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>was 142 x 10^9/L, <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore>was 0.02x10^9/l. On 07 Apr 2008, <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>was 140 x 10^9/L, <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore>was 0.07x10^9/l. On 03 Jun 2008, <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>was 136 x 10^9/L and <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore>was 0.12x10^9/l. On 30 Jun 2008, <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>was 194 x 10^9/L and <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore>was 0.12x10^9/l. On 26 Mar 2012, the patient laboratory data showed <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>was 126 x 10^9/L, <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore>was 0.22x10^9/l and <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">mean <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>volume </Semaphore>was 9.5 fl. On 23 Apr 2012, the patient laboratory data showed <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">mean <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>volume </Semaphore>was 9.1 fl, <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>was 135 x 10^9/L, <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>levels was 137umol/L, <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore>was 0.16x10^9/l and estimated <Semaphore x="1986326" class="Disease or Finding" value="Glomerular Filtration Rate Decreased" score="1.00" ID="C78326">glomerular filtration rate </Semaphore>was 48ml/min/1.73m^2. Reporter stated that, the patient laboratory data <Semaphore x="2592399" class="Race" value="Sugpiaq" score="1.00" ID="C44488">suggest </Semaphore>moderately impaired renal function<Semaphore x="1779284" class="Disease or Finding" value="Chronic Kidney Disease, Stage 3" score="1.00" ID="C80389">, stage 3 CKD (<Semaphore x="1779418" class="Disease or Finding" value="Chronic Kidney Disease" score="1.00" ID="C80078">chronic <Semaphore x="2088512" class="AnatomicStructure" value="Kidney" score="1.00" ID="C12415">kidney </Semaphore>disease</Semaphore></Semaphore>). On 03 Dec 2012 the patient laboratory data showed <Semaphore x="1410372" class="Procedure" value="Absolute Neutrophil Count" score="1.00" ID="C63321">neutrophils </Semaphore>count was 80% (<Semaphore x="2933880" class="MedDRA LLT" value="Eosinophil count normal" score="1.00" ID="10014946">normal range (40-75), <Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore></Semaphore>was 02% and <Semaphore x="2138646" class="Procedure" value="Lymphocyte Count" score="1.00" ID="C51949"><Semaphore x="2138646" class="Procedure" value="Lymphocyte Count" score="1.00" ID="C51949">lymphocytes </Semaphore>count </Semaphore>was 17% (20-45). The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.87" ID="247865">Clozaril </Semaphore>was continued. The seriousness criterion for the event <Semaphore x="2804249" class="MedDRA LLT" value="Blood creatinine decreased" score="1.00" ID="10005482"><Semaphore x="2050560" class="Disease or Finding" value="Increased Creatinine" score="1.00" ID="C78249">creatinine <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>increased</Semaphore>, <Semaphore x="2978897" class="MedDRA LLT" value="Glomerular filtration rate decreased" score="1.00" ID="10018358"><Semaphore x="1986427" class="Procedure" value="Glomerular Filtration Rate" score="1.00" ID="C90505">GFR </Semaphore>decreased </Semaphore></Semaphore>was reported as medically significant, and the seriousness criterion for the event <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053"><Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528"><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore><Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528"><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">count <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">decreased</Semaphore></Semaphore>
        <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
         , <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">mean <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore></Semaphore></Semaphore></Semaphore>
       <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
        <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
         <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
          </Semaphore></Semaphore></Semaphore></Semaphore>
      <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
       <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
        <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
         </Semaphore></Semaphore></Semaphore></Semaphore>
     <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
      <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
       <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
        <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">volume </Semaphore></Semaphore>
       </Semaphore></Semaphore>
     <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
      </Semaphore></Semaphore>
    <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
     <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">increased </Semaphore></Semaphore>was reported as non serious, while for other events seriousness criterion was not reported. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>for the event <Semaphore x="2804249" class="MedDRA LLT" value="Blood creatinine decreased" score="1.00" ID="10005482"><Semaphore x="2804296" class="MedDRA LLT" value="Blood creatinine increased" score="1.00" ID="10005483"><Semaphore x="2050560" class="Disease or Finding" value="Increased Creatinine" score="1.00" ID="C78249">creatinine <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore><Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">increased</Semaphore></Semaphore>
      <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">
       </Semaphore></Semaphore>
     <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">
      <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">, <Semaphore x="1986427" class="Procedure" value="Glomerular Filtration Rate" score="1.00" ID="C90505">GFR </Semaphore><Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">decreased</Semaphore>
       <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
        <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">
         </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">
     <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">
      <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
       <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">
        <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">, <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>
          </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
     <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
      <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">
       <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
        <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
         <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">count </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
     <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">
      <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
       <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
        <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">decreased</Semaphore>
        <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
         , <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">mean <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
      <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
       <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
        <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
         <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
          </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
     <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
      <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
       <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
        <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
         </Semaphore></Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
     <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
      <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
       <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
        <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">volume </Semaphore></Semaphore>
       </Semaphore></Semaphore>
     <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
      </Semaphore></Semaphore>
    <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
     <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">increased </Semaphore></Semaphore>was reported as ongoing, while for other events <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was not reported. <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">Outcome </Semaphore>of the event <Semaphore x="2933828" class="MedDRA LLT" value="Eosinophil count decreased" score="1.00" ID="10014943"><Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil count </Semaphore>decreased </Semaphore>was reported as completely recovered and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count decreased </Semaphore>was reported as condition improving. The causality for the event <Semaphore x="2804249" class="MedDRA LLT" value="Blood creatinine decreased" score="1.00" ID="10005482"><Semaphore x="2050560" class="Disease or Finding" value="Increased Creatinine" score="1.00" ID="C78249">creatinine <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>increased</Semaphore>, <Semaphore x="2978897" class="MedDRA LLT" value="Glomerular filtration rate decreased" score="1.00" ID="10018358"><Semaphore x="1986427" class="Procedure" value="Glomerular Filtration Rate" score="1.00" ID="C90505">GFR </Semaphore>decreased </Semaphore></Semaphore>was reported as not suspected, and the causality for the event <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053"><Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528"><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore><Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528"><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">count <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">decreased</Semaphore></Semaphore>
        <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
         , <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">mean <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore></Semaphore></Semaphore></Semaphore>
       <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
        <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
         <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
          </Semaphore></Semaphore></Semaphore></Semaphore>
      <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
       <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
        <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
         </Semaphore></Semaphore></Semaphore></Semaphore>
     <Semaphore x="3100742" class="MedDRA LLT" value="Mean platelet volume decreased" score="1.00" ID="10055053">
      <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
       <Semaphore x="2206681" class="Procedure" value="Mean Platelet Volume Measurement" score="1.00" ID="C74730">
        <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">volume </Semaphore></Semaphore>
       </Semaphore></Semaphore>
     <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
      </Semaphore></Semaphore>
    <Semaphore x="3100759" class="MedDRA LLT" value="Mean platelet volume increased" score="1.00" ID="10055052">
     <Semaphore x="3189588" class="MedDRA LLT" value="Platelet count increased" score="1.00" ID="10051608">increased </Semaphore></Semaphore>was reported as suspect, while for other events causality was not reported.Follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 05 Dec 2012: Laboratory data of 03 Dec 2012, <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events <Semaphore x="2933828" class="MedDRA LLT" value="Eosinophil count decreased" score="1.00" ID="10014943"><Semaphore x="1889898" class="Procedure" value="Eosinophil Count" score="1.00" ID="C64550">eosinophil <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">count </Semaphore></Semaphore>
     <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
      <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">decreased </Semaphore></Semaphore></Semaphore>
    <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
     <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">
      <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">
       <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">
        <Semaphore x="3189557" class="MedDRA LLT" value="Platelet count decreased" score="1.00" ID="10035528">and <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>
         </Semaphore>count </Semaphore></Semaphore>decreased </Semaphore></Semaphore>updated.</narrativeincludeclinical>
				<sendercomment>Based on Review of available reported data does not allow for a proper causality assessment. Reported event is unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>